At least six people died and 30 were wounded in a shooting at a July Fourth parade in the Chicago suburb of Highland Park. Here's what we know and don't know about the shooting. What we know:Six people have been killed Police have identified a person of interest as Robert Crimo III, a 22-year-old who lives in the area, according to police.Police arrested the Crimo just before 7 p.m. CST in Lake Forest, Illinois, a suburb near Highland Park.Police believe the shooter fired on the parade from a rooftop using a rifle that was recovered at the scene. Police say they believe there is only one shooter.Some of the victims have been identified. Nicolas Toledo was in his late 70s and visiting from Mexico when he was shot. He died at the scene, his granddaughter told the Chicago Sun-Times. Also killed was Jacki Sundheim, a lifelong congregant and “beloved” staff member at nearby North Shore Congregation Israel, which announced her death on its website. What we don't know: Police have not said whether or not they are aware of the shooter's motive.Police have only identified the weapon as a high-powered rifle.The Associated Press contributed to this report.

Tropical Storm Arlene formed Friday afternoon after hurricane hunters determined Tropical Depression 2 had strengthened.

This content is imported from Twitter.
You may be able to find the same content in another format, or you may be able to find more information, at their web site.

Arlene was located 265 miles west of Fort Myers, Florida, and 340 miles north-northwest of the western tip of Cuba as of 2 p.m. Friday.

The storm had maximum sustained winds of 40 mph and was moving south at 5 mph.

"Although the storm has strengthened slightly, we still expect Arlene to weaken soon due to increasing wind shear and dry air, and no change has been made to the forecast," the National Hurricane Center said.

Arlene is headed south and won't directly impact the states, though Florida will have rainfall related to the storm.

Rainfall amounts of 1 to 2 inches with localized higher amounts up to 5 inches are possible through Saturday across portions of the central and southern Florida Peninsula.

Arlene is the first named storm of the year. We had a subtropical system develop in the northern Atlantic back in January.

HUNTINGTON BEACH, Calif. —

Crews raced Sunday morning to contain the damage from a major oil spill off the Orange County coast that left crude spoiling beaches, killing fish and birds and threatening local wetlands.

The oil slick is believed to have originated from a pipeline leak, pouring 126,000 gallons into the coastal waters and seeping into the Talbert Marsh as lifeguards deployed floating barriers known as booms to try to stop further incursion, said Jennifer Carey, Huntington Beach city spokesperson.

At sunrise Sunday, oil was on the sand in some parts of Huntington Beach with slicks visible in the ocean as well.

"We classify this as a major spill, and it is a high priority to us to mitigate any environmental concerns," Carey said. It's all hands on deck."

CNN —

The U.S. Food and Drug Administration authorized Johnson & Johnson's COVID-19 vaccine Saturday. It is the first single dose COVID-19 vaccine available in the U.S. and is one that "checks nearly all the boxes."

With more than 28.5 million confirmed COVID-19 cases and over 511,000 reported deaths in the U.S. since the start of the pandemic, and while the demand for vaccine still far exceeds supply, these vaccines can't come soon enough.

"A third safe and effective vaccine is very welcome news," Andy Slavitt, the White House's senior for COVID Response, tweeted on Friday.

The vaccine, made by Janssen, J&J's vaccine arm, is safe and effective, and it's considered flexible. It's a single dose, and it doesn't require special storage.

The vaccine is authorized for people ages 18 and older.

"We need a vaccine that can be quickly mass produced," Dr. Greg Poland, head of the Mayo Clinic's Vaccine Research Group, said Friday. "We'd want to see a reasonable duration of efficacy and protection.

"The Janssen vaccine candidate checks nearly all the boxes."

The vaccine was tested in more than 44,000 people in the U.S., South Africa and Latin America. Globally, it was 66.1% effective against moderate to severe/critical COVID-19 at least four weeks after vaccination, according to an FDA analysis. In the U.S., it is considered 72% effective, and offered 86% protection against severe forms of the disease.

"One dose will keep you out of the hospital, keep you out of the intensive care unit, and keep you out of the morgue," Dr. Paul Offit, a vaccine adviser to the FDA, told CNN's Wolf Blitzer on Friday.

The vaccine comes with few side effects, most of which are mild, including pain at the injection site, headache, fatigue and muscle pain.

Overall, non-fatal serious adverse events were infrequent, according to the FDA's analysis, and there were no reported cases of anaphylaxis following vaccination in the trial. There have been a small number of severe allergic reactions with the Moderna and Pfizer/BioNTech vaccines. For example, in the first week of the Pfizer vaccine rollout, there were only 29 cases out of 1.9 million doses administered, according to the U.S. Centers for Disease Control and Prevention.

More research is needed, but the FDA analysis also hinted that the J&J vaccine may help prevent asymptomatic infections.

A January study from the CDC showed that most coronavirus cases are spread by people without symptoms. If a vaccine prevented asymptomatic infection, it might help reduce opportunities to transmit the disease — not just keep the vaccinated from getting sick.

With so much positive data, an independent group of advisers voted unanimously on Friday to recommend the emergency use authorization of the J&J vaccine.

"I think it's a relatively easy call. It clearly gets way over the bar, and it's nice to have a single-dose vaccine," Dr. Eric Rubin, a member of the committee who is also the editor in chief of The New England Journal of Medicine and a professor at the Harvard T.H. Chan School of Public Health, said after the vote.

There is some concern that because the public has heard that the shot is only 72% protective in the U.S., and the Pfizer and Moderna COVID-19 vaccines are about 95% protective, some will think this is a "second class" vaccine, but the experts say those numbers are highly misleading.

"It's difficult to make an apples-to-apples comparison between vaccines authorized based on data collected before new variants are believed to have been in widespread circulation," said Sarah Christopher, the policy advocacy director at the National Women's Health Network. Christopher spoke during the public comment section of the FDA's advisory meeting on Friday.

The Pfizer and Moderna COVID-19 vaccines were tested earlier in the pandemic when there were fewer known variants. FDA research found that the majority of the cases that happened during the South African part of the J&J trial came from a newer and possibly more contagious variant.

Public health experts say people should take whatever shot is first available to them.

"If I had a J&J vaccine available today and a Moderna vaccine available tomorrow, I would be happy to take the J&J today. I don't feel like I would need to wait. They are all terrific vaccines for the things that we care about," Dr. Ashish Jha, dean of the Brown University School of Public Health, told a House Ways and Means Health Subcommittee hearing Friday.

Experts have said variants may fuel a surge of cases in the spring in the U.S., and say that's one reason why it's important to get as many people vaccinated as quickly as possible.

"We'll be seeing how much of an impact the variants have and how best these vaccines can address them, whether it will be booster doses, or other vaccines," said Dr. Aditya Gaur, a co-lead investigator on the J&J trial at St. Jude in Memphis. "But I think one could not have asked for better from this first round of vaccine development from a standpoint of how quickly it has happened and how quickly it has started to roll out around the world."

On Sunday, the CDC's Advisory Committee on Immunization Practices, known as ACIP, will meet to set the guidelines for who should get the vaccine. Their vote is scheduled for 3 p.m. ET.

From there, the much needed vaccine could start rolling out to vaccine centers around the country.

While the initial supply is limited — the company says it only has about 4 million doses of its vaccine ready to ship "immediately" — it should have 20 million ready by the end of March.

The advancement of the Johnson & Johnson coronavirus vaccine is "really good news for the world," Dr. Francis Collins, director of the National Institutes of Health, told CNN's Wolf Blitzer on Friday. Even with cases in the U.S. declining recently, the pandemic is far from over. "The best way to get done is with this vaccine being added to the others."

This year’s Grammys might be a far cry from typical years, with the ongoing coronavirus pandemic drastically reducing the number of celebrities present at the ceremony. Still, Grammy producers didn’t relinquish the star power so easily—they ensured some performers and nominees will still attend in person. Although the red carpet might not demonstrate the dazzle of years past, expect plenty of showstopper gowns and get-ups regardless; these quarantine-exhausted celebs are desperate for a fashion moment.

If you’re wondering whether to tune in, Grammy Awards executive producer Ben Winston promised Variety this year’s show will give us plenty of access to our favorite stars: “The performers and nominees are each other’s audience, so it’s a room of incredible musicians, all safely distanced from each other, and every 45 minutes, a new four groups come in and the [previous] four go out,” he explained.